Chong Kun Dang said on the 10th that it has recently unveiled back-to-back research results for new drug candidates for anticancer therapy and obesity and metabolic diseases at major international conferences held in the United States.
On the 2nd (local time), at World ADC 2025 in San Diego, the United States, Chong Kun Dang presented preclinical (animal and cell) study results for CKD-703, an antibody-drug conjugate (ADC)-based anticancer candidate. CKD-703 is a new drug candidate that combines next-generation drug delivery technology with an antibody targeting the c-Met protein, which supports cancer cell growth, and is characterized by selectively attacking only cancer cells. The candidate received phase 1 and 2a clinical approval from the U.S. Food and Drug Administration (FDA) in July and is in clinical trials for patients with non-small cell lung cancer and solid tumors.
In preclinical results, CKD-703 showed ▲ high binding affinity to c-Met ▲ rapid intracellular delivery to cancer cells ▲ improved stability in blood ▲ improved tolerability, and it also demonstrated excellent tumor suppression across various cancer models. The company said it "may offer a precision targeted therapy option to a broader range of cancer patients."
On the 4th, at Obesity Week 2025 in Atlanta, the United States, it presented study results for CKD-514, an oral GLP-1 class candidate for obesity and metabolic diseases. CKD-514 improved absorption through enhanced solubility, showed weight-loss effects at lower doses than Orforglipron, an oral obesity drug under development by global corporations, in animal studies, and at the same dose demonstrated superior blood glucose-lowering effects.
A follow-up candidate also showed metabolic improvement effects that were equivalent or superior to Orforglipron and semaglutide (brand name Ozempic). The company said it expects that "developing an oral obesity drug will strengthen competitiveness in a global market dominated by injectables."
In addition, on the 7th at SITC 2025 in Maryland, the United States, Chong Kun Dang introduced preclinical results for CKD-512, an immuno-oncology candidate. CKD-512 is a new drug candidate that restores immune responses by blocking the adenosine A2A receptor (A2AR), which suppresses immune cell activity around tumors. A phase 1 clinical trial is underway in Korea, and the company has received clinical approval in Taiwan and is preparing a study.
In preclinical testing, CKD-512 showed ▲ high binding affinity for A2AR ▲ restoration of immune cell function ▲ enhancement of immune responses within the tumor environment, and it demonstrated strong synergy when combined with immuno-oncology agents and existing anticancer treatments, the company said.
A Chong Kun Dang official said, "From ADC anticancer drugs to oral obesity treatments and immuno-oncology agents, the competitiveness of our key pipeline has been recognized on the global stage," adding, "We will accelerate the development of innovative new drugs based on the differentiation confirmed in preclinical studies."